Serum insulin degrading enzyme level and other factors in type 2 diabetic patients with mild cognitive impairment

Current Alzheimer Research

Volumn 13, Issue 12, 2016, Pages 1337-1345

  Suna, Jie ^a,b   Xia, Wenqing ^c   Cai, Rongrong ^a   Wang, Pin ^a   Huang, Rong ^a   Sun, Haixia ^a   Tian, Sai ^a   Dong, Xue ^a   Wang, Shaohua ^a  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Homeostasis model of assessment for insulin resistance; Insulin degrading enzyme; Mild cognitive impairment; The mean amplitude of glycemic excursions; The trail making test B; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULINASE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN;

ADULT; AGED; ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MONTREAL COGNITIVE ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TRAIL MAKING TEST; BLOOD; COGNITIVE DEFECT; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COGNITIVE DYSFUNCTION; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBINS; HUMANS; INSULIN RESISTANCE; INSULYSIN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 84995968135     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160615091043     Document Type: Article

References (44)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365(9467): 1333-46 (2005)
2. van Elderen SG, de Roos A, de Craen AJ, Westendorp RG, Blauw GJ, Jukema JW, et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology 75(11): 997-1002 (2010)
3. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ 328(7439): 548 (2004)
4. Okereke OI, Kang JH, Cook NR, Gaziano JM, Manson JE, Buring JE, et al. Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults. J Am Geriatr Soc 56(6): 1028-36 (2008)
5. Yaffe K, Lindquist K, Schwartz AV, Vitartas C, Vittinghoff E, Satterfield S, et al. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 77(14): 1351-6 (2011)
6. Hassing LB, Hofer SM, Nilsson SE, Berg S, Pedersen NL, McClearn G, et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 33(4): 355-61 (2004)
7. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 10(9): 819-28 (2011)
8. Strachan MW, Price JF, Frier BM. Diabetes, cognitive impairment, and dementia. BMJ 336(7634): 6 (2008)
9. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. Diabetes 56(1): 211-6 (2007)
10. Kahn SE. The relative contributions of insulin resistance and betacell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46(1): 3-19 (2003)
11. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122(4): 1316-38 (2012)
12. Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature 511(7507): 94-8 (2014)
13. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev 19(5): 608-24 (1998)
14. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, et al. Partial loss-of-function mutations in insulindegrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 164(4): 1425-34 (2004)
15. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100(7): 4162-7. (2003)
16. Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. Diabetes Med 28(12): 1463-75 (2011)
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 15(7): 539-53 (1998)
18. Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer’s Disease. J Neurol Neurosurg Psychiatry 77(6): 714-8 (2006)
19. Ryan CM, Geckle M. Why is learning and memory dysfunction in Type 2 diabetes limited to older adults? Diabetes Metab Res Rev 16(5): 308-15 (2000)
20. Panza F, Frisardi V, Seripa D, Imbimbo BP, Sancarlo D, D’Onofrio G, et al. Metabolic syndrome, mild cognitive impairment, and dementia. Curr Alzheimer Res 8(5): 492-509 (2011)
21. S Roriz-Filho J, Sa-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 1792(5): 432-43 (2009)
22. Young SE, Mainous AG, 3rd, Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 29(12): 2688-93 (2006)
23. Palta P, Schneider AL, Biessels GJ, Touradji P, Hill-Briggs F. Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. J Int Neuropsychol Soc 20(3): 278-91 (2014)
24. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 29(4): 494-511 (2008)
25. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53(7): 1270-87 (2010)
26. Naylor MD, Karlawish JH, Arnold SE, Khachaturian AS, Khachaturian ZS, Lee VM, et al. Advancing Alzheimer’s disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. Alzheimers Dement 8(5): 445-52 (2012)
27. Umegaki H. Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: vascular changes or neurodegeneration? Age Ageing 39(1): 8-10 (2010)
28. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J Neurosci 24(49): 11120-6 (2004)
29. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, et al. Dietinduced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J 18(7): 902-4 (2004)
30. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer’s disease. Neurobiol Aging 28(6): 824-30 (2007)
31. Backer JM, Kahn CR, Cahill DA, Ullrich A, White MF. Receptormediated internalization of insulin requires a 12-amino acid sequence in the juxtamembrane region of the insulin receptor betasubunit. J Biol Chem 265(27): 16450-4 (1990)
32. Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci U S A 100(10): 6221-6 (2003)
33. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35(11 Suppl 1): 2628-31 (2004)
34. Bugaiska A, Clarys D, Jarry C, Taconnat L, Tapia G, Vanneste S, et al. The effect of aging in recollective experience: the processing speed and executive functioning hypothesis. Conscious Cogn 16(4): 797-808 (2007)
35. Turner GR, Spreng RN. Executive functions and neurocognitive aging: dissociable patterns of brain activity. Neurobiol Aging 33(4): 826e1-13 (2012)
36. Ramirez J, McNeely AA, Scott CJ, Stuss DT, Black SE. Subcortical hyperintensity volumetrics in Alzheimer’s disease and normal elderly in the Sunnybrook Dementia Study: correlations with atrophy, executive function, mental processing speed, and verbal memory. Alzheimers Res Ther 6(4): 49 (2014)
37. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol 7(2): 184-90 (2008)
38. Li ZG, Zhang W, Grunberger G, Sima AA. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res 946(2): 221-31 (2002)
39. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865): 813-20 (2001)
40. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer’s disease. J Int Neuropsychol Soc 14(2): 266-78 (2008)
41. Rapp MA, Reischies FM. Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE). Am J Geriatr Psychiatry 13(2): 134-41 (2005)
42. Convit A. Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 26(1): 31-5 (2005)
43. Schuur M, Henneman P, van Swieten JC, Zillikens MC, de Koning I, Janssens AC, et al. Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study. Eur J Epidemiol 25(8): 561-8 (2010)
44. Abbatecola AM, Paolisso G, Lamponi M, Bandinelli S, Lauretani F, Launer L, et al. Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 52(10): 1713-8 (2004)